Drug intelligence / Profile preview

ProgenaMatrix

Development stage
Unknown
Lead developer
Venture Medical
Modality
Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

ProgenaMatrix is a novel, advanced wound care product constructed from human keratin protein. It is the first and only commercially available human keratin matrix designed to assist in wound repair by providing a moist healing environment and supporting the body’s natural healing processes. The matrix is non-cellular, not tissue-based, resistant to degradation, and bio-inspired to activate both keratinocytes and fibroblasts while modulating immune response. Indicated for dry and exuding partial- and full-thickness wounds—including venous stasis ulcers, diabetic foot ulcers, pressure ulcers, burns (first- and second-degree), surgical wounds, donor sites/grafts—ProgenaMatrix offers an alternative to porcine or other tissue-based products with no cultural or religious barriers. It has FDA 510(k) clearance as a skin substitute device for wound management[1][2][5][6].

Brand names
ProgenaMatrix
Other names
human keratin grafthuman keratin matrixHKM
02

Targets

Keratinocyte cell surface adhesion proteinsMMP1 (Matrix metalloproteinase-1)MMP9 (Matrix metalloproteinase-9)

Beyond the preview

Go deeper on ProgenaMatrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProgenaMatrix.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call